Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Gains from Sales and Divestitures (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $387925.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to $387925.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $387925.0, a N/A change, with the full-year FY2018 number at $149243.0, changed N/A from a year prior.
  • Gains from Sales and Divestitures was $387925.0 for Q3 2025 at Whitehawk Therapeutics, up from $325000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $387925.0 in Q3 2025 to a low of $63000.0 in Q1 2025.